A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs Dapagliflozin (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DEPICT 1
  • Sponsors AstraZeneca; Bristol-Myers Squibb
  • Most Recent Events

    • 26 Jun 2018 Results of an analysis using pooled data from DEPICT 1 and DEPICT 2 studies, presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
    • 26 Jun 2018 Results of pooled analysis of continuous glucose monitoring data from DEPICT 1 and DEPICT 2 trial presented at the 78th Annual Scientific Sessions of the American Diabetes Association
    • 26 Jun 2018 Long-term efficacy and safety results presented at the 78th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top